AstraZeneca leaves door ajar to Pfizer, despite hurdles Reuters India Buoyed by progress with its new drug pipeline - including a lung cancer medicine called AZD9291 for which data was released late on Wednesday - Soriot believes AstraZeneca can enjoy a strong independent future, but he has left the door ajar to a ... |
